are there differences between structurally different angiotensin-converting enzyme inhibitors?
It is well established that angiotensin-converting enzyme (ACE) inhibitors (ACEI) reduce blood pressure (BP) and hypertrophy of the left ventricle and vessels. The aim of our study was to compare chemically different ACEIs regarding their ability to modulate left ventricular and media hypertrophy, ACE activity and plasma endothelin-1 concentrations in spontaneously hypertensive rats (SHRs).
Related Questions
- Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
- SHOULD ALL PATIENTS WITH TYPE 1 DIABETES MELLITUS AND MICROALBUMINURIA RECEIVE ANGIOTENSIN-CONVERTING ENZYME INHIBITORS?
- Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?